News & Events

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care

https://ascopubs.org/doi/full/10.1200/JCO.20.02953

Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).

https://meetinglibrary.asco.org/record/186976/slide

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179

https://pubmed.ncbi.nlm.nih.gov/32697352/

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

https://pubmed.ncbi.nlm.nih.gov/31160171/

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

https://pubmed.ncbi.nlm.nih.gov/32661186/

An experiment in end-of-life care: Tapping AI’s cold calculus to nudge the most human of conversations

https://www.statnews.com/2020/07/01/end-of-life-artificial-intelligence/

Cancer Care Associates of York Joins the Quality Cancer Care Alliance’s National Network

https://www.newswire.com/news/cancer-care-associates-of-york-joins-the-quality-cancer-care-alliances-21160679

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

https://www.ncbi.nlm.nih.gov/pubmed/30487236 Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC,… A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Aligning With Cancer Centers To Spur Biosimilar Uptake

https://www.biosimilardevelopment.com/doc/aligning-with-cancer-centers-to-spur-biosimilar-uptake-0001

Reducing Cancer Costs Through Symptom Management and Triage Pathways.

Barkley R1, Soobader MJ2, Wang J2, Blau S3, Page RD4.https://www.ncbi.nlm.nih.gov/pubmed/30576262